Noble Life Sciences

Executive Summary

Noble Life Sciences is a preclinical CRO founded in 2004, headquartered in Gaithersburg, Maryland. The company offers comprehensive preclinical development and bioanalytical services, including formulation, analytical testing, pharmacodynamic modeling, and GLP-compliant safety studies. It supports programs in small molecules, biologics, cell and gene therapy, and medical devices, helping clients accelerate from discovery through IND-enabling stages. As a private company with no disclosed funding or valuation, Noble Life Sciences operates in the competitive CRO market, leveraging its specialized expertise to serve biotech and pharmaceutical clients. The company's steady position in the preclinical space suggests moderate growth potential, with opportunities to expand through strategic partnerships or service enhancements.

Upcoming Catalysts (preview)

• Q4 2026Expansion of bioanalytical service offerings or facility upgrades60% success
• Q2 2027Strategic partnership or collaboration with a major pharma company40% success
• Q3 2026Achievement of regulatory milestone (e.g., IND-enabling study completion for a key client)50% success